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Diabetes mellitus (DM) is a global health issue; the
worldwide prevalence of the adult diabetic population is
projected to reach one-half billion people in 2030.
Currently, one-fourth of the diabetic U.S. population is
treated with insulin (ITDM) (1,2). Atherosclerosis and its
phenotypic manifestations are accelerated in DM, as coro-
nary artery disease (CAD) more often displays complex
multivessel disease with a higher risk of in-stent restenosis
and stent thrombosis (scaffold/stent thrombosis [ST]) after
percutaneous coronary intervention (PCI). Progression of
CAD and stent complications in DM are driven by the
combined effects of hyperglycemia, insulin resistance, and
free fatty acids, resulting in endothelial dysfunction with
impaired vasodilation, increased monocyte migration, neo-
intimal hyperplasia, and platelet reactivity (3,4).See pages 471 and 482Compared with bare metal stents, ﬁrst-generation drug-
eluting stents (DESs) markedly decreased the rate of reste-
nosis in patients with diabetes; however, safety concerns
regarding late ST were documented in both diabetic and
nondiabetic patients. Drug deliverability was improved in
second-generation DESs, which have been evaluated in
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paper to disclose.rates after percutaneous coronary intervention (PCI) are still
considerably higher than in patients without diabetes;
however, those rates are primarily driven by ITDM (3). The
FREEDOM (Future Revascularization Evaluation in Pa-
tients with Diabetes Mellitus: Optimal Management of
Multivessel Disease) trial showed that patients with ITDM
also had more cardiovascular events than patients with non-
ITDM after both multivessel PCI and coronary artery
bypass procedure (CABG). Furthermore, event rates after
PCI (mostly with ﬁrst-generation DESs) were uniformly
higher than after CABG in both the ITDM and non-
ITDM strata and the event curves only separated after 2
to 3 years (5), suggesting the particular long-term implica-
tions of DM in the diffuse nature of CAD and the limita-
tions of DESs. Therefore, all new-generation DESs should
be studied in patients with DM and long-term follow-up
should be mandatory.
No head-to-head comparisons have been performed to
date between everolimus-eluting stents (EES) and zotar-
olimus-eluting stents (ZES) or everolimus-eluting bio-
resorbable vascular scaffolds (BVS) in patients with DM. In
this issue of JACC: Cardiovascular Interventions, 2 studies
with such comparisons are reported (6,7).
Patients with DM may be prone to long-term vascular
inﬂammation caused by the durable polymer or the perma-
nent local metal endoprosthesis of second-generation DESs.
However, technological advances have enabled the creation
of new types of DESs with bioresorbable polymer and
scaffold. In the comparison of EES with BVS, Muramatsu
et al. (6) present promising results at 1 year. In patients with
BVS, the incidence of target lesion failure (TLF), cardiac
death, myocardial infarction (MI), and ischemia-driven
target lesion revascularization (ID-TLR) was numerically
lower in patients with diabetes (3.7%) compared with pa-
tients without (5.1%). Virtually every other study conducted
in the era of stenting has shown higher event rates in pa-
tients with diabetes (8). Diabetic patients with a BVS had
nonsigniﬁcantly lower rates of TLF and ST than matched
patients with EES.
In the pooled analysis of diabetic patients from the
SPIRIT FIRST (A Clinical Trial of the Abbott Vascular
XIENCE V Everolimus Eluting Coronary Stent System),
SPIRIT II (A Clinical Evaluation of the XIENCE V
Everolimus Eluting Coronary Stent System), SPIRIT III
(Clinical Trial of the XIENCE V Everolimus Eluting
Coronary Stent System [EECSS]), SPIRIT IV Clinical
Trial (Clinical Evaluation of the XIENCE V Everolimus
Eluting Coronary Stent System), ABSORB Cohort B, and
ABSORB EXTEND trial, the SPIRIT IV trial was the
largest contributor of patients with cobalt-chromium EES.
Inclusion criteria in the SPIRIT IV trial were, however,
more liberal and included patients with complex lesions, as
opposed to the ABSORB trials. The authors have tried to
overcome these baseline population differences by ﬁtting a
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495model for propensity scores with variables of angiographic
lesion complexity, but 25% of patients from the SPIRIT
trials had to be excluded as they had missing baseline
characteristics necessary to compute the propensity score.
The ﬁnal matched comparison of BVS and EES conse-
quently rested on few and highly selected patients. Due to
the restrictive angiographic inclusion criteria in ABSORB,
the severity of diabetes in the patients with an implanted
BVS was presumably milder than in the diabetic background
population, also indicated by the similar baseline charac-
teristics between the diabetes and nondiabetes group with a
BVS and by the comparatively low prevalence of insulin use,
a known marker for complications (3,4) that was conﬁrmed
in this study.
Despite the caveats and risk of residual bias, this study
provides an early and, to date, the only indication of a
favorable proﬁle of BVS, as suggested by the reduced
event rate, albeit nonsigniﬁcantly, compared with EES in
diabetic patients with noncomplex lesions. However, these
results may very well be due to a type II error. It will be
interesting to see the long-term follow-up data at 2 years
and beyond because some of the beneﬁcial effects of BVS
(e.g., absence of permanent vessel caging, which facilitates
restoration of vasomotor function; adaptive shear stress; cy-
clic strain; and late luminal enlargement [9]) cannot be ex-
pected at 1 year. Restoration of vasomotor function might be
of particular interest in diabetes as decreased nitric oxide
production by endothelial dysfunction decreases vasodilation.
Conversely, EES have been studied in diabetes before. In
a pooled analysis from the SPIRIT II through IV and
COMPARE (Comparison of the Everolimus Eluting
XIENCE-V Stent with the Paclitaxel Eluting TAXUS
LIBERTÉ Stent in All-comers: A Randomized Open La-
bel Trial) trials, EES signiﬁcantly reduced mortality, MI,
and ST, compared with ﬁrst-generation paclitaxel-eluting
stents (PES) in patients without diabetes (8). However, a
highly signiﬁcant interaction was identiﬁed between DM
and stent type for 2-year clinical outcome. In diabetic pa-
tients, EES failed to improve safety and efﬁcacy over PES
(8). Additionally, in non-ITDM, ID-TLR was reduced
with EES, whereas in ITDM, a trend toward increased ID-
TLR was seen compared with PES (8). In the following
randomized SPIRIT V diabetic study (10), lumen loss and
1-year cardiac death or MI was signiﬁcantly reduced with
EES. However, the ID-TLR rate was, again, considerably
higher with EES and more than 2-fold increased com-
pared with PES. In contrast, the ESSENCE-DIABETES
(Everolimus-Eluting Stent Versus Sirolimus-Eluting Stent
Implantation for de Novo Coronary Artery Disease in Pa-
tients with Diabetes Mellitus) study found an extremely low
ID-TLR rate with EES, which could have been due to a
much smaller proportion of ITDM in the ESSENCE-
DIABETES study among patients with EES compared
with the SPIRIT V diabetic study.These hypothesis-generating data may be explained by
the different mechanisms through which paclitaxel (PES)
and rapamycin (EES and ZES) analogs reduce in-stent
restenosis. Paclitaxel interferes with pathways of in-stent
restenosis by disrupting microtubular function that affects
smooth muscle cell proliferation and migration, extracellular
matrix production, and intercell signaling. The effects of
paclitaxel are hence diverse and may therefore be relatively
independent of the diabetic state. Conversely, rapamycin
only interferes with mitosis that is tightly regulated by
glycosylation-dependent enzymes, which in turn may be
affected by hyperglycemia. Stone et al. (8) showed an
increasing gradient of event rates among patients treated
with EES, with event rates lowest in nondiabetic patients,
intermediate in non-ITDM patients, and highest in ITDM
patients. No such relationship was apparent in patients
treated with PES. Whether the explanation lies in differ-
ences between insulin-deﬁcient and -resistant states or in a
direct effect of insulin on vascular response to second-
generation limus eluting stents is unknown (8).
Park et al. (7) compared the XIENCE EES and Resolute
ZES (R-ZES) in 1,855 all-comer diabetic patients. After
unrestricted use, despite a higher risk proﬁle in R-ZES
patients, both the EES and R-ZES showed comparable and
low incidences of TLF (3.5%) and ST (0.3%) at 1 year,
suggesting excellent safety of both stent types. Patient-
related outcomes were, however, 3-fold higher than stent-
related outcomes, stressing the importance of integrated
secondary prevention and medical management of comor-
bidities in diabetes.
The efﬁcacy of the EES and R-ZES was more difﬁcult to
evaluate. Rates for any MI, including target vessel, nontarget
vessel, and ST (0.8% for the EES and 0.6% for the ZES),
were much lower than in previous studies, as systematic
collection of cardiac enzymes after PCI is not routine
practice in South Korea, and several centers have same-day
discharge standards. Both stent- and patient-related out-
comes included MI and were hence most likely under-
reported and not generalizable. Conversely, an optional
angiography was performed at 9 months, which might have
inﬂated the patient-related outcome, which included any
revascularization. However, this was a systemic bias and,
therefore, we do learn from this study that the EES and
R-ZES most likely perform equally in DM.
Second-generation stent scaffolds with rapamycin-eluting
durable polymers certainly have improved safety proﬁles with
very low ST risk also in diabetic patients. It is still unknown
whether this advantage will translate in parallel into efﬁcacy
or is hampered by the possible effects of hyperglycemia on
limus eluting stents or inﬂammation-mediated restenotic
responses of the diabetic milieu to new durable stent poly-
mers. In this context, the results of everolimus-eluting BVS
are promising and may constitute an attractive treatment
alternative. Currently, however, the perspective for patients
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496with diabetes and complex multivessel disease remains;
CABG may still be the way to go, even with the improved
second-generation DESs. The ongoing EXCEL (Evalua-
tion of XIENCE Everolimus Eluting Stent Systems Versus
Coronary Artery Bypass Surgery for Effectiveness of Left
Main Revascularization) trial among patients with DM will
provide answers.
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